Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Company Deals

Innovent Biologics Secures $1.1B Global CD40L Antibody Deal with Spero Therapeutics

Fineline Cube Jul 15, 2026
Company Deals

Hansoh Pharmaceutical Secures $2.3B IL-23 Deal and Strategic Stake in Avere-NextCure Merger

Fineline Cube Jul 15, 2026
Company Deals

Everest Medicines and JD Healthcare Forge Strategic Digital Healthcare Alliance to Accelerate Innovative Drug Access

Fineline Cube Jul 15, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy

Fineline Cube Jul 16, 2026
Company Drug

Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity

Fineline Cube Jul 16, 2026
Company Drug

Bristol-Myers Squibb’s Breyanzi Hits Primary Endpoint in Lymphoma Study

Fineline Cube Feb 11, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) reported positive results from the Phase II TRANSCEND FL study...

Company Drug

CSPC Pharmaceutical’s SYH2039 Wins FDA Clinical Approval for Advanced Tumors

Fineline Cube Feb 11, 2025

China’s CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that the U.S. Food and Drug Administration...

Company Drug

Boehringer Ingelheim’s Nerandomilast Hits Primary Endpoint in PPF Phase III Study

Fineline Cube Feb 11, 2025

German pharma giant Boehringer Ingelheim announced positive topline results from the Phase III FIBRONEER-ILD study...

Company Drug

CSPC Pharmaceutical’s Omalizumab Biosimilar Wins NMPA Approval for Allergic Asthma

Fineline Cube Feb 11, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has received an additional indication approval from the...

Company Drug

Kelun-Biotech to Present SKB264/MK-2870 Data for Urothelial Carcinoma at ASCO-GU 2025

Fineline Cube Feb 11, 2025

China’s Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990) will present efficacy and safety data from...

Company Drug

Sinopep-Allsino Wins NMPA Approval for Generic Liptruzet in China

Fineline Cube Feb 11, 2025

Jiangsu-based CDMO Sinopep-Allsino Biopharmaceutical Co., Ltd (SHA: 688076) has received marketing approval from China’s National...

Company Deals

R-Nanoablation Raises USD 13.7M in Series B+ to Advance Nanosecond Ablation Tech

Fineline Cube Feb 11, 2025

Hangzhou-based R-Nanoablation, a minimally invasive medical device developer, has raised over RMB 100 million (USD...

Company Deals

Bio-Thera Solutions Licenses BAT2506 to Intas Pharmaceuticals for US Market

Fineline Cube Feb 10, 2025

China-based Bio-Thera Solutions Inc. (SHA: 688177) announced that it has entered into a licensing agreement...

Company Drug

Changchun GeneScience’s GenSci120 Receives NMPA Approval for Rheumatoid Arthritis Trials

Fineline Cube Feb 10, 2025

China-based Changchun GeneScience Pharmaceutical Co., Ltd announced that it has received another clinical trial approval...

Company Drug

CARsgen’s Allogeneic BCMA CAR-T Therapy Achieves sCR in First Patient

Fineline Cube Feb 10, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that the first patient treated with its...

Company

Haisco Pharmaceutical Group Registers Delaware Subsidiary to Expand Global Operations

Fineline Cube Feb 10, 2025

Shenzhen-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced the registration of a new...

Company Drug

Beijing Luzhu Submits BLA for LZ901 Herpes Zoster Vaccine to NMPA

Fineline Cube Feb 10, 2025

Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a human vaccine and therapeutic biologics manufacturer, announced...

Company Drug Hospital

Hainan Boao Lecheng Pilot Zone Implements Baclofen Intrathecal Therapy

Fineline Cube Feb 10, 2025

The Hainan Boao Lecheng Pilot Zone Management Bureau announced the implementation of Baclofen Intrathecal Sintetica,...

Company Deals

Xtalpi Invests in Alternative Bio for Cancer and Inflammation Drugs

Fineline Cube Feb 10, 2025

Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., announced a strategic investment in...

Policy / Regulatory

NMPA’s New Guidelines for Drug Registration Review

Fineline Cube Feb 10, 2025

A Look at the New Rules for Chemical and Biological Drug Filings in China:The Center...

Policy / Regulatory

Shanghai’s Three-Year Plan to Boost Elderly Care Quality

Fineline Cube Feb 10, 2025

A Comprehensive Look at Shanghai’s Efforts to Integrate Medical Care and Elderly Care:The Shanghai Civil...

Company Drug

NMPA Approves Sinocelltech’s Finotonlimab for Head and Neck Cancer

Fineline Cube Feb 10, 2025

The National Medical Products Administration (NMPA) of China has approved Sinocelltech Group Ltd’s (SHA: 688520)...

Policy / Regulatory

Tianjin Municipality Boosts Biopharmaceutical Industry with New Measures

Fineline Cube Feb 10, 2025

An In – Depth Look at Tianjin’s Efforts to Accelerate Medical Innovation and Gather Resources:The...

Company Drug

Hansoh Pharma’s Uplizna Receives Priority Review for IgG4-RD Treatment

Fineline Cube Feb 10, 2025

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that the National Medical Products Administration (NMPA)...

Policy / Regulatory

NMPA Seeks Public Feedback on Export Drug Manufacturing Rules

Fineline Cube Feb 10, 2025

An In – Depth Look at the New Draft Proposal for the Administration and Management...

Posts pagination

1 … 245 246 247 … 695

Recent updates

  • Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy
  • Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity
  • Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia
  • China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD
  • Roche Secures FDA Priority Review for Gazyva in Primary Membranous Nephropathy Based on Phase III MAJESTY Data
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures Dual NMPA Approvals for HRS-8797 Atopic Dermatitis Drug and HRS-8829 Stroke Therapy

Company Drug

Ascletis Pharma Selects ASC30_48 FDC as First-in-Class Oral Dual GIPR/GLP-1R Agonist for Obesity

Company Drug

Fosun Pharma Secures NMPA Approval for FXR0906, Liver-Targeted siRNA Therapy for Hypertriglyceridemia

Company Drug

China Medical System Secures NMPA Approval for CMS-D017, Novel Complement Factor B Inhibitor for AMD

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.